Skip to search formSkip to main contentSkip to account menu

EMD 273063 antibody, human

Known as: Hu 14.18/IL - 2 Fusion Protein, hu14.18-interleukin-2 fusion protein, EMD 273063 
A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

8 relations
Cytotoxic T-LymphocytesNCIt Antineoplastic Agent TerminologyReceptor Activation ProcessT-Cell Activation

Broader (2)

Interleukin-2Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract 4011: Effectivein situimmunization via local radiation therapy (RT) and tumor-specific immunocytokine (IC): Suppression from distant tumor is blocked by RT or Treg-depleting CTLA-4 antibody
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA PURPOSE: Use “off the shelf” reagents to… 
2015
2015
Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model
We have identified a cooperative interaction between radiation and intratumoral injection of anti-GD2 immunocytokine (hu14.18-IL2… 
2014
2014
A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma.
9044 Background: Phase I testing of the hu14.18-IL2 immunocytokine (IC), a mAb reactive with GD2 disialoganglioside, linked to… 
2013
2013
Abstract 2858: Binding characteristics of the immunocytokine hu14.18-IL2 and induction of human effector functions as anticipated mode of action.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Immunotherapy of neuroblastoma with anti-GD2… 
2012
2012
Abstract 1538: Enhanced antitumor effects of intratumoral (IT) hu14.18-IL2 immunocytokine (IC) compared to intravenous (IV) hu14.18-IL2 are distinguished by increased activated tumor infiltrating…
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Introduction: Hu14.18-IL2 (APN301, Apeiron… 
2012
2012
Preclinical and clinical development of intratumorally administered hu14.18-IL2 as treatment for neuroblastoma and melanoma: the importance of tumor infiltrating leukocytes in tumors treated with…
2010
2010
Genotypes of NK cell KIR Receptors , Their Ligands , and Fc γ Receptors in the Response of Neuroblastoma Patients to Hu 14 . 18-IL 2 Immunotherapy : A Children ’ s Oncology Group Report #
Response to immunocytokine (IC) therapy is dependent on natural killer (NK) cells in murine neuroblastoma (NBL) models… 
Review
2008
Review
2008
Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children’s Oncology Group (COG) phase II study
3002 Background: The hu14.18-IL2 fusion protein consists of IL2 linked to a humanized mAb that recognizes the GD2… 
2008
2008
Phase II trial of hu14.18-IL2 (EMD 273063) for patients with metastatic melanoma
9039 Background: The hu14.18-IL2 immunocytokine consists of a humanized anti-GD2 monoclonal antibody linked to IL2. It has potent… 
2001
2001
Immunozytokine
Immuntherapie von Krebs hat eine lange Geschichte. Die bisher erfolgreichsten Ansätze beruhen auf Antikörpern (AK) mit einer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)